RemeGen's (HKG:9995, SHA:688331) attributable loss narrowed to 1.47 billion yuan in 2024 from 1.51 billion yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.
Loss per share at the biopharmaceutical company narrowed to 2.73 yuan from 2.80 yuan in the previous year. Analysts at Visible Alpha estimated loss per share of 2.50 yuan.
Revenue increased 58% to 1.72 billion yuan from 1.08 billion yuan a year earlier, in line with Visible Alpha estimates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.